> Detailanzeige
Hochhaus, Andreas
[Verfasser:in];
Réa, Delphine
[Verfasser:in];
Boquimpani, Carla
[Verfasser:in];
Minami, Yosuke
[Verfasser:in];
Cortes, Jorge E.
[Verfasser:in];
Hughes, Timothy P.
[Verfasser:in];
Apperley, Jane F.
[Verfasser:in];
Lomaia, Elza
[Verfasser:in];
Voloshin, Sergey
[Verfasser:in];
Turkina, Anna
[Verfasser:in];
Kim, Dong-Wook
[Verfasser:in];
Abdo, Andre
[Verfasser:in];
Fogliatto, Laura Maria
[Verfasser:in];
le Coutre, Philipp
[Verfasser:in];
Sasaki, Koji
[Verfasser:in];
Kim, Dennis Dong Hwan
[Verfasser:in];
Saußele, Susanne
[Verfasser:in];
Annunziata, Mario
[Verfasser:in];
Chaudhri, Naeem
[Verfasser:in];
Chee, Lynette
[Verfasser:in];
García-Gutiérrez, Valentin
[Verfasser:in];
Kapoor, Shruti
[Verfasser:in];
Allepuz, Alex
[Verfasser:in];
Quenet, Sara
[Verfasser:in];
[...]
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors : longer-term follow-up of ASCEMBL
- Beteiligte: Hochhaus, Andreas [Verfasser:in]; Réa, Delphine [Verfasser:in]; Boquimpani, Carla [Verfasser:in]; Minami, Yosuke [Verfasser:in]; Cortes, Jorge E. [Verfasser:in]; Hughes, Timothy P. [Verfasser:in]; Apperley, Jane F. [Verfasser:in]; Lomaia, Elza [Verfasser:in]; Voloshin, Sergey [Verfasser:in]; Turkina, Anna [Verfasser:in]; Kim, Dong-Wook [Verfasser:in]; Abdo, Andre [Verfasser:in]; Fogliatto, Laura Maria [Verfasser:in]; le Coutre, Philipp [Verfasser:in]; Sasaki, Koji [Verfasser:in]; Kim, Dennis Dong Hwan [Verfasser:in]; Saußele, Susanne [Verfasser:in]; Annunziata, Mario [Verfasser:in]; Chaudhri, Naeem [Verfasser:in]; Chee, Lynette [Verfasser:in]; García-Gutiérrez, Valentin [Verfasser:in]; Kapoor, Shruti [Verfasser:in]; Allepuz, Alex [Verfasser:in]; Quenet, Sara [Verfasser:in]; Bédoucha, Véronique [Verfasser:in]; Mauro, Michael J. [Verfasser:in]
-
Erschienen:
March 2023
- Erschienen in: Leukemia ; 37(2023), 3, Seite 617-626
- Sprache: Englisch
- DOI: 10.1038/s41375-023-01829-9
- Identifikator:
- Schlagwörter: Chronic myeloid leukaemia ; Targeted therapies
- Entstehung:
-
Anmerkungen:
Online veröffentlicht: 30. Januar 2023
- Beschreibung: Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with ≥2 prior TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily. Consistent with previously published primary analysis results, after a median follow-up of 2.3 years, asciminib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib. The major molecular response (MMR) rate at week 96 (key secondary endpoint) was 37.6% with asciminib vs 15.8% with bosutinib; the MMR rate difference between the arms, after adjusting for baseline MCyR, was 21.7% (95% CI, 10.53-32.95; two-sided p = 0.001). Fewer grade ≥3 adverse events (AEs) (56.4% vs 68.4%) and AEs leading to treatment discontinuation (7.7% vs 26.3%) occurred with asciminib than with bosutinib. A higher proportion of patients on asciminib than bosutinib remained on treatment and continued to derive benefit over time, supporting asciminib as a standard of care for patients with CML-CP previously treated with ≥2 TKIs.
- Zugangsstatus: Freier Zugang